The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study

被引:32
|
作者
Bahadir, Aysenur [1 ]
Kurucu, Nilgun [2 ]
Kadioglu, Mine [3 ]
Yenilmez, Engin [4 ]
机构
[1] Karadeniz Tech Univ, Sch Med, Dept Pediat Hematol, Trabzon, Turkey
[2] Ankara Oncol Hosp, Dept Pediat Oncol, Ankara, Turkey
[3] Karadeniz Tech Univ, Sch Med, Dept Pharmacol, Trabzon, Turkey
[4] Karadeniz Tech Univ, Sch Med, Dept Histol, Trabzon, Turkey
关键词
Doxorubicin; Nitric oxide; Nitric oxide synthase inhibitors; HEART-FAILURE; RAT-HEART; SYNTHASE; CARDIOMYOPATHY; DYSFUNCTION; ADRIAMYCIN; TOXICITY; SUPEROXIDE; ERDOSTEINE; PREVENTION;
D O I
10.4274/Tjh.2013.0013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We evaluated the myocardial damage in rats treated with doxorubicin (DOX) alone and in combination with nitric oxide synthase (NOS) inhibitors. Materials and Methods: Twenty-four male Sprague Dawley rats (12 weeks old, weighing 262 +/- 18 g) were randomly assigned into 4 groups (n=6). Group I was the control group. In Group II, rats were treated with intraperitoneal (ip) injections of 3 mg/kg DOX once a week for 5 weeks. In Group III, rats received weekly ip injections of 30 mg/kg L-NAME (nonspecific NOS inhibitor) 30 min before DOX injections for 5 weeks. In Group IV, rats received weekly ip injections of 3 mg/kg L-NIL (inducible NOS inhibitor) 30 min before DOX injections for 5 weeks. Rats were weighed 2 times a week. At the end of 6 weeks, hearts were excised and then fixed for light and electron microscopy evaluation and tissue lipid peroxidation (malondialdchyde). Blood samples were also obtained for measuring plasma lipid peroxidation. Results: Weight loss was observed in Group II, Group III, and Group IV. Weight loss was statistically significant in the DOX group. Findings of myocardial damage were significantly higher in animals treated with DOX only than in the control group. Histopathological findings of cardiotoxicity in rats treated with DOX in combination with L-NAME and L-NIL were not significantly different compared with the control group. The level of plasma malondialdehyde in the DOX group (9.3 +/- 3.4 mu mol/L) was higher than those of all other groups. Conclusion: Our results showed that DOX cardiotoxicity was significantly decreased when DOX was given with NO synthase inhibitors.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 50 条
  • [41] Evolution of Theories on Doxorubicin-Induced Late Cardiotoxicity-Role of Topoisomerase
    Szponar, Jaroslaw
    Ciechanski, Erwin
    Ciechanska, Magda
    Dudka, Jaroslaw
    Mandziuk, Slawomir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
  • [42] Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
    Liu, Hao
    Wang, Haiyan
    Xiang, Dingcheng
    Guo, Wangang
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2017, 17 (01) : 44 - 50
  • [43] Mitigating Doxorubicin-Induced Cardiotoxicity through Quercetin Intervention: An Experimental Study in Rats
    Dulf, Patricia Lorena
    Coada, Camelia Alexandra
    Florea, Adrian
    Moldovan, Remus
    Baldea, Ioana
    Dulf, Daniel Vasile
    Blendea, Dan
    Filip, Adriana Gabriela
    ANTIOXIDANTS, 2024, 13 (09)
  • [44] Iron metabolism in doxorubicin-induced cardiotoxicity: From mechanisms to therapies
    Ye, Hua
    Wu, Lin
    Liu, Yanmei
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2024, 174
  • [45] The significance of the apelinergic system in doxorubicin-induced cardiotoxicity
    Matusik, Katarzyna
    Kaminska, Katarzyna
    Sobiborowicz-Sadowska, Aleksandra
    Borzuta, Hubert
    Buczma, Kasper
    Cudnoch-Jedrzejewska, Agnieszka
    HEART FAILURE REVIEWS, 2024, 29 (05) : 969 - 988
  • [46] Oxidative stress injury in doxorubicin-induced cardiotoxicity
    Mei Songbo
    Hong Lang
    Cai Xinyong
    Xiao Bin
    Zhang Ping
    Shao Liang
    TOXICOLOGY LETTERS, 2019, 307 : 41 - 48
  • [47] Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice
    Fan, Rui
    Wang, Yao
    Zhang, Jinjin
    An, Xiangbo
    Liu, Shuang
    Bai, Jie
    Li, Jiatian
    Lin, Qiuyue
    Xie, Yunpeng
    Liao, Jiawei
    Xia, Yunlong
    PHARMACEUTICALS, 2023, 16 (09)
  • [48] Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
    Cheah, Irwin K.
    Tang, Richard M. Y.
    Wang, Xiaoyuan
    Sachaphibulkij, Karishma
    Chong, Suet Yen
    Lim, Lina H. K.
    Wang, Jiong-Wei
    Halliwell, Barry
    ANTIOXIDANTS, 2023, 12 (02)
  • [49] MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity
    Holmgren, Gustav
    Synnergren, Jane
    Andersson, Christian X.
    Lindahl, Anders
    Sartipy, Peter
    TOXICOLOGY IN VITRO, 2016, 34 : 26 - 34
  • [50] Repeated Remote Ischemic Conditioning Reduces Doxorubicin-Induced Cardiotoxicity
    He, Quan
    Wang, Fangfei
    Ryan, Thomas D.
    Chalasani, Meghana
    Redington, Andrew N.
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 41 - 52